Guardant Health, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Guardant Health, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $982.02M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $739.02M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $563.95M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $449.54M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $373.65M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $286.73M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $214.38M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $90.64M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $49.84M | Mar 2, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $982.02M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $739.02M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $563.95M | Feb 19, 2026 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($416.28M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($436.37M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($479.45M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($654.59M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | ($384.77M) | Feb 22, 2024 |
| FY2019 | Dec 31, 2019 | ($75.65M) | Mar 2, 2020 |
| FY2019 | Dec 31, 2018 | ($85.06M) | Mar 2, 2020 |
| FY2019 | Dec 31, 2017 | ($83.22M) | Mar 2, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($437.25M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($443.59M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($564.73M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($544.38M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | ($411.00M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | ($254.95M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | ($82.37M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($92.94M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($76.61M) | Mar 2, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $364.19M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $347.75M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $367.19M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $373.81M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $263.22M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $149.86M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $86.29M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $50.71M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $25.56M | Mar 2, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($184.76M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($239.86M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($324.98M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($309.46M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | ($209.02M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | ($103.93M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | ($47.13M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($72.19M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($72.24M) | Mar 2, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.31M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $35.09M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $20.49M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $77.46M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $75.04M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $36.17M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $18.72M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $20.20M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $6.68M | Mar 2, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.01B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.49B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.79B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.61B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $2.20B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $2.27B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $962.54M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $587.40M | Mar 2, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.11B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.63B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.63B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.55B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $1.56B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $916.19M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $114.54M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $62.45M | Mar 2, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($99.31M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($139.65M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $158.68M | Feb 19, 2026 |
| FY2025 | Dec 31, 2022 | $60.18M | Feb 19, 2026 |
| FY2024 | Dec 31, 2021 | $645.01M | Feb 20, 2025 |
| FY2023 | Dec 31, 2020 | $1.30B | Feb 22, 2024 |
| FY2022 | Dec 31, 2019 | $798.39M | Feb 23, 2023 |
| FY2021 | Dec 31, 2018 | $483.15M | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | $308.61M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $79.70M | Mar 2, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $77.26M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.29M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $3.29M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $3.29M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $3.29M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $3.29M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $3.29M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Mar 2, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.99B) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($2.58B) | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | ($2.14B) | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | ($1.66B) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($1.01B) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($606.59M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($352.81M) | Feb 25, 2021 |
| FY2019 | Jan 1, 2019 | ($275.89M) | Mar 2, 2020 |
| FY2019 | Dec 31, 2018 | ($280.80M) | Mar 2, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $378.20M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $525.54M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.13B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $141.65M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $492.20M | Feb 22, 2024 |
| FY2021 | Dec 31, 2020 | $832.98M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $143.23M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $140.54M | Mar 2, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.50B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.14B | Feb 19, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | (4) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | (6) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | (4) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 24, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | (4) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | (6) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | (4) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 24, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 130.64M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 123.99M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 121.63M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | 102.62M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 101.77M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 100.21M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 94.26M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 85.83M | Mar 2, 2020 |